SCHEMBL6674766

SCHEMBL6674766

C=CCOC(=O)N1CCC(CO)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 1/20 0.39
NR1D1 P20393 1/20 0.39
THRB P10828 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALOX5 P09917 1/20 0.36
TEAD1 P28347 1/20 0.36
TEAD3 Q99594 1/20 0.36
NOS3 P29474 1/20 0.35
NOS2 P35228 1/20 0.35
TPSAB1 Q15661 2/20 0.35
TPSD1 Q9BZJ3 2/20 0.35
TPSG1 Q9NRR2 2/20 0.35
EPHX2 P34913 1/20 0.35
CHRM1 P11229 2/20 0.34
CHRM4 P08173 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9198701 0.90 NR1D1 (0.44) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL31097156 0.85 TPSAB1 (0.47) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL8353411 0.85 GAA (0.45) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL31097155 0.85 TPSAB1 (0.47) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL9194031 0.83 NR1H2 (0.38) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL3248801 0.83 GPR119 (0.42) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL9697742 0.83 GAA (0.40) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL5139985 0.81 EPHX2 (0.40) RAB9ALMNAMAPK1NR1D1EPHX2
SCHEMBL4234377 0.81 FAAH (0.39) GPR119RAB9ALMNAMAPK1GAA
SCHEMBL13597248 0.81 TSHR (0.43) GPR119RAB9ALMNAMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282796-A1 PENEM ANTIBACTERIALS AGAINST MYCOBACTERIAL PATHOGENS AND D,D- AND L,D TRANSPEPTIDASES THE JOHNS HOPKINS UNIVERSITY 2025-09-11 US disclosed
WO-2004035544-A1 BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GLAXO GROUP LIMITED (GB) 2004-04-29 WO disclosed
EP-0394991-B1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO (JP) 1994-08-17 EP disclosed
US-5102877-A Carbapenicillin antibiotics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-07 US disclosed
EP-0394991-A1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282796-A1 PENEM ANTIBACTERIALS AGAINST MYCOBACTERIAL PATHOGENS AND D,D- AND L,D TRANSPEPTIDASES PEPD, DNPEP, NAALAD2 GPR119 4270/4885RAB9A 2188/4885LMNA 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.